Oncology News | pharmaphorum

News

AMPLIFY results dial up Calquence's potential in CLL

AstraZeneca's Calquence has hit the mark in the phase 3 AMPLIFY trial in chronic lymphocytic leukaemia (CLL), a study that chief executive Pascal Soriot recently said could be a "blockbuste

News

Third Arc's $165m for T cell engagers, plus other bio rounds

This week's round-up of new financings in the biotech world is headed by a big round for Third Arc, a specialist in T-cell engager antibodies, with Autobahn, Brenig, Confo, and GRO Bio also

News

ODAC unpicks AZ's Imfinzi trial in perioperative NSCLC

FDA reviewers were so frustrated by AstraZeneca's application for Imfinzi as a treatment before and after surgery for resectable non-small cell lung cancer (NSCLC) that they voted for a ret

News

Ipsen builds again, licensing Day One glioma drug

Ipsen has signed yet another portfolio-expanding deal – its fifth of the year so far – claiming rights outside the US to a drug for common brain cancer glioma from Day One Biopharmaceutical

News

European big pharmas raise guidance on stronger sales

AstraZeneca, Roche, and Sanofi released their second-quarter results today, with a common theme – strong sales growth that caused them to raise their financial guidance for the year.

News

NICE backs first 'take at home' prostate cancer pill

Thousands of men in the UK with advanced hormone-sensitive prostate cancer could soon be eligible for an oral therapy – Accord Healthcare's Orgovyx – that can be taken at home rather than r

AMPLIFY results dial up Calquence's potential in CLL

Third Arc's $165m for T cell engagers, plus other bio rounds

ODAC unpicks AZ's Imfinzi trial in perioperative NSCLC

Ipsen builds again, licensing Day One glioma drug

European big pharmas raise guidance on stronger sales

NICE backs first 'take at home' prostate cancer pill

Delivering the right behavioural ingredients for the moment,...

How to meet your physicians where they are online

News

Editor's Picks